Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Site Tools

  • AAAS
  • Subscribe
  • Feedback

Site Search

Search Advanced

Science 15 July 1988:
Vol. 241. no. 4863, pp. 357 - 359
DOI: 10.1126/science.3388046
Prev | Table of Contents | Next

Articles

Science, Vol 241, Issue 4863, 357-359
Copyright © 1988 by American Association for the Advancement of Science

articles

Type-restricted neutralization of molecular clones of human immunodeficiency virus

DJ Looney, AG Fisher, SD Putney, Rusche JR, RR Redfield, DS Burke, RC Gallo, and F Wong-Staal

Department of Viral Diseases, Walter Reed Army Institute of Research, Washington, DC 20307.

In a study of the immunologic significance of the genetic diversity present within single isolates of human immunodeficiency virus type 1 (HIV-1), the neutralization of viruses derived from molecular clones of the HIV-1 strain HTLV-IIIB by an extensive panel of sera was compared. Sera from HIV-1-infected patients and from goats immunized with polyacrylamide gel-purified HIV-1 envelope glycoprotein (gp120), native gp120, or gp120-derived recombinant peptides, showed marked heterogeneity in neutralizing activity against these closely related viruses. The change of a single amino acid residue in gp120 may account for such "clonal restriction" of neutralizing activity.


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Acquired Immunodeficiency Syndrome-- A Review and Update: History, Characteristics of Human Immunodeficiency Virus Infection, Its Replication, Biologic Factors, and Pathogenicity.
N. W. Fox and C. P. McArthur (1993)
Arch Fam Med 2, 1068-1077
   Abstract »    PDF »
Selective transmission of human immunodeficiency virus type-1 variants from mothers to infants.
S. Wolinsky, C. Wike, B. Korber, C Hutto, W. Parks, L. Rosenblum, K. Kunstman, M. Furtado, and J. Munoz (1992)
Science 255, 1134-1137
   Abstract »    PDF »
Antigenic diversity thresholds and the development of AIDS.
M. Nowak, R. Anderson, A. McLean, T. Wolfs, J Goudsmit, and R. May (1991)
Science 254, 963-969
   Abstract »    PDF »
Long-term high-titer neutralizing activity induced by octameric synthetic HIV-1 antigen.
C. Wang, D. Looney, M. Li, A. Walfield, J Ye, B Hosein, J. Tam, and F Wong-Staal (1991)
Science 254, 285-288
   Abstract »    PDF »
LAV revisited: origins of the early HIV-1 isolates from Institut Pasteur.
S Wain-Hobson, J. Vartanian, M Henry, N Chenciner, R Cheynier, S Delassus, L. Martins, M Sala, M. Nugeyre, D Guetard, et al. (1991)
Science 252, 961-965
   Abstract »    PDF »
The Safety and Immunogenicity of a Human Immunodeficiency Virus Type 1 (HIV-1) Recombinant gp160 Candidate Vaccine in Humans.
R. Dolin, B. S. Graham, S. B. Greenberg, C. O. Tacket, R. B. Belshe, K. Midthun, M. L. Clements, G. J. Gorse, B. W. Horgan, R. L. Atmar, et al. (1991)
Ann Intern Med 114, 119-127
   Abstract »    PDF »
Broadly neutralizing antibodies elicited by the hypervariable neutralizing determinant of HIV-1.
K Javaherian, A. Langlois, G. LaRosa, A. Profy, D. Bolognesi, W. Herlihy, S. Putney, and T. Matthews (1990)
Science 250, 1590-1593
   Abstract »    PDF »
Development and Evaluation of a Vaccine for Human Immunodeficiency Virus (HIV) Infection.
A. S. Fauci, R. C. Gallo, S. Koenig, J. Salk, and R. H. Purcell (1989)
Ann Intern Med 110, 373-385
   Abstract »    PDF »


To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)